# Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer

> **NCT00525096** · PHASE3 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 157 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** placebo
- **DRUG:** Celecoxib
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT00525096
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2011-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525096, "Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00525096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*